Small-molecule oral TKI combined with low-toxicity chemotherapeutic drug will probably provide a novel regimen for low-risk HER2 + breast cancer with less AE, comparable efficacy, better compliance, and reduced socio-economic burden compared with current standard adjuvant therapy. This evidence concerns the gene ERBB2 and breast carcinoma.